Coronary artery disease. Atherosclerotic heart disease of native coronary artery
Conditions
Interventions
Intervention 1: Intervention group: recieving 300000 internatinal unit cholecalciferol orally 12 hours before Percutaneous Coronary Intervention (Daana Pharma). Intervention 2: Intervention group: rec
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: All patients diagnosed with Coronary artery disease who hospitalized due to performing elective percutaneous Coronary Intervention (angioplasty with stent) Vitamin D level of less than 30 ng/mL
Exclusion criteria
Exclusion criteria: patients with myocardial infarction or history of coronary artery bypass graft in last 3 months patients with history of vitamin D supplementation in the last 1 month prior to hospitalization patients with history of unsuccessful PCI
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison any change in level of troponin-I. Timepoint: at baseline and 24 hours after Percutaneous Coronary Intervention. Method of measurement: serum level.;Comparison any change in level of High Sensitivity C-Reactive Protein (hsCRP). Timepoint: At baseline and 24 hours after Percutaneous Coronary Intervention. Method of measurement: serum level.;Comparison any change in level of Creatine kinase-MB. Timepoint: At baseline and 24 hours after Percutaneous Coronary Intervention. Method of measurement: serum level. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Laleh Mahmoudi
Shiraz University of Medical Sciences
Outcome results
None listed